Application of local microbes increases growth and yield of several local upland rice cultivars of Southeast Sulawesi, Indonesia

Rice is the major food commodity in Indonesia and many other countries, as the main source of carbohydrate. Rice production must be increased continuously to meet food needs, one of which is by utilizing largely available dry land areas. Two important factors required to increase rice production on marginal soils are the use of high-production adaptive varieties and biological agents. It is necessary to conduct research on the application of local microbes to the cultivation of upland rice cultivars, with the aim to determine the best genotypes and/or suitable microbes. This research was carried out at the Research Field and laboratories of Faculty of Agriculture, University of Halu Oleo, from April 2020 to April 2021. The first tested factor was biological agents (local microbes), consisting of three levels, namely: without microbes (M0), the fungus Trichoderma sp. (M1), and the bacteria Pseudomonas sp. (M2). The second factor was the upland rice cultivar, which consisted of five levels, namely: V1 (Tinangge cultivar), V2 (Enggalaru cultivar), V3 (Bakala cultivar), V4 (Momea cultivar), and 1 nasional variety, namely V5 (Inpago-12 variety), as check variety. The research results showed that the interaction between local microbes Trichoderma sp. (M1) and Pseudomonas sp. (M2) on Tinangge (V1) and Momea (V4) cultivars gave a better effect on crop production. The best cultivar based on the growth and yield variables was generally obtained from the Momea cultivar (V4), although in many variables it was not significantly different from the Tinangge cultivar (V1). These cultivars could be further studied and possibly developed for promising cultivars in Kendari areas.

Effectiveness of Indigenous Rhizobacteria Formulations in Increasing the Growth and Yield of Shallots (Allium ascalonicum L.)

The use of beneficial microbes in increasing plant growth and yield is a very appropriate choice to reduce synthetic chemicals that can cause negative impacts on the environment. The purpose of this study was to evaluate the effectiveness of post-save formulations of Wakatobi indigenous rhizobacteria in increasing the growth and yield of shallots. The study was conducted in Jati Bali Village, Konawe Selatan District, using a Randomized Block Design, consisting of 10 rhizobacterial formulation treatments, a combination of three types of biological agents, namely Pseudomonas sp. LP03, Pseudomonas sp. TWB02 and Pseudomonas sp. TWB11, and three types of formulation materials: ground brick powder, ground burned rice husk powder, and bentonite; one control using NaCl 0.85%. The experiment was repeated three times so that there were 360 treatment units. The results showed that of the three types of rhizobacteria tested, only Pseudomonas sp. TWB02 and Pseudomonas sp. LP03 can display better performance in increasing the growth and yield of shallots. These rhizobacteria are more compatible using the ground burned rice-husk powder formulation. Increased shallot yield (tuber fresh weight) in seed treatment using Pseudomonas sp. TWB02 and Pseudomonas sp. LP03 in the formulation of ground burned rice-husk powder reached 121% and 117% compared to controls. Further research needs to be done on a broader scale and different environmental conditions to see the stability of these biological agents' effects on the growth and yield of shallots.

Comparative efficacy of tocilizumab and baricitinib in COVID-19 treatment: a retrospective cohort study

Background Although the biological agents tocilizumab and baricitinib have been shown to improve the outcomes of patients with COVID-19, a comparative evaluation has not been performed. The aim of our study was to evaluate the comparative effect of the use of tocilizumab and baricitinib on patient outcomes in COVID-19. Methods A retrospective, single-center study was conducted using the data of patients with COVID-19 admitted to Hokkaido University hospital between April 2020 and September 2021 and were treated with tocilizumab or baricitinib. The clinical characteristics of the patients who received each drug were compared. Univariate and multivariate logistic regression analyses were performed against the outcomes of all-cause mortality and the improvement in respiratory status. The development of secondary infection events was analyzed using the Kaplan–Meier method and the log-rank test. Results Among the 459 patients hospitalized with COVID-19 during the study, 64 received tocilizumab and 34 received baricitinib, and they were included in the study. Most patients were treated with concomitant steroids, and the severity of the disease at the time of initiation of biological agents was similar. The use of tocilizumab or baricitinib was not associated with all-cause mortality or the improvement in respiratory status within 28 days of drug administration. Age, chronic renal disease, and comorbid respiratory disease were independent prognostic factors for all-cause mortality, whereas anti-viral drug use and severity of COVID-19 at baseline were associated with the improvement in respiratory status. There was no significant difference in the infection-free survival rate between patients treated with tocilizumab and those with baricitinib. Conclusion There were no differences in efficacy and safety between tocilizumab and baricitinib in the treatment of COVID-19. Both these biological agents are expected to be equally safe and clinically effective.

Vasculitis induced by biological agents used in rheumatology practice: A systematic review

Objectives: Biological medications have been used with an increasing frequency to treat rheumatological diseases. Autoimmune events can be induced by these drugs, such as psoriasiform lesions, alopecia, lupus and, vasculitis, which more often affects the skin (small-sized vessels) and eventually other organs. In this review, we describe the clinical profile of patients with vasculitis induced by the main biological agents used in rheumatology. Patients and methods: We performed a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations. The PubMed database was used for searching eligible articles. We included case reports, case series, and letter to the editor of patients on anti-tumor necrosis factor-alpha (anti-TNF-a) molecules, as well as tocilizumab, ustekinumab, secukinumab, rituximab, and abatacept, who had vasculitis induced by these agents. Results: Eighty-one articles were included for final analysis (n=89). Twenty-seven patients were using infliximab, 20 adalimumab, 18 etanercept, seven secukinumab, four certolizumab, four rituximab, three golimumab, three ustekinumab, two abatacept, and one tocilizumab. Unspecific leukocytoclastic vasculitis (LCV) was the most common type of vasculitis (n=37), followed by anti-neutrophil cytoplasmic antibody (ANCA)- associated vasculitis (n=16). The medication was replaced with another biological molecule in 23 cases, with only four relapses. In six cases, the biological was maintained, but vasculitis worsened/persisted in one case, being necessary drug removal. Conclusion: Infections, infusion reaction, cancer, and autoimmune events are well-known side effects of biological therapy. This review demonstrates that vasculitis is another adverse effect of this type of therapy, particularly the anti-TNF-a molecules, and LCV the most reported type of vasculitis.

Biologics for Psoriasis During the COVID-19 Pandemic

Coronavirus disease 2019 (COVID-19), a new form of acute infectious respiratory syndrome first reported in 2019, has rapidly spread worldwide and has been recognized as a pandemic by the WHO. It raised widespread concern about the treatment of psoriasis in this COVID-19 pandemic era, especially on the biologics use for patients with psoriasis. This review will summarize key information that is currently known about the relationship between psoriasis, biological treatments, and COVID-19, and vaccination-related issues. We also provide references for dermatologists and patients when they need to make clinical decisions. Currently, there is no consensus on whether biological agents increase the risk of coronavirus infection; however, current research shows that biological agents have no adverse effects on the prognosis of patients with COVID-19 with psoriasis. In short, it is not recommended to stop biological treatment in patients with psoriasis to prevent the infection risk, and for those patients who tested positive for SARS-CoV-2, the decision to pause biologic therapy should be considered on a case-by-case basis, and individual risk and benefit should be taken into account. Vaccine immunization against SARS-CoV-2 is strictly recommendable in patients with psoriasis without discontinuation of their biologics but evaluating the risk-benefit ratio of maintaining biologics before vaccination is mandatory at the moment.

Physicochemical, Sensory and Nutritional Properties of Foods Affected by Processing and Storage

Due to their chemical composition and physicochemical characteristics, most foods are very perishable and are easily altered by physical, chemical and biological agents [...]